Skip to main content

Table 2 ACT Clinical Trials for PDAC

From: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma

NCT number

Status

Intervention

Phase

Duration

Location

NCT03008304

Recruiting

High-activity natural killer

Phase 1

Phase 2

December 2016–December 2019

Fuda Cancer Institute of Fuda Cancer Hospital, Guangzhou, Guangdong, China

NCT03267173

Recruiting

Chimeric antigen receptor T cell

Phase 1

June 15, 2017-June 2019

Harbin Medical University, Harbin, Heilongjiang, China

NCT03180437

Recruiting

γδ T cell

Phase 1

Phase 2

June 15, 2017-June 15, 2020

Biotherapy Centre at Fuda Cancer Hospital, Guangzhou, Guangdong, China

NCT03136406

Active, not recruiting

aNK

Phase 1

Phase 2

August 14, 2017-December 2018

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

NCT03329248

Active, not recruiting

haNK

Phase 1

Phase 2

November 6, 2017-December 2019

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

NCT02929797

Recruiting

CD8 + NKG2D+ AKT cells

Early Phase 1

August 2016–August 2019

Shanghai General Hospital, Shanghai, China

NCT03323944

Recruiting

huCART-meso cells

Phase 1

September 15, 2017-September 2021

University of Pennsylvania, Philadelphia, Pennsylvania, United States

NCT02718859

Unknown

NK cells

Phase 1

Phase 2

March 2016–March 2017

Central Laboratory at Fuda Cancer Hospital, Guangzhou, Guangdong, China

NCT01781520

Completed

DC-CIK

Phase 1

Phase 2

June 1, 2013-June 13, 2017

Capital Medical University Cancer Center, Beijing, Beijing, China

NCT03387098

Active, not recruiting

haNK

Phase 1

Phase 2

January 2, 2018-December 2019

Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States

NCT00003780

Unknown

Tumour-infiltrating lymphocytes

Phase 2

December 1998, the last update posted is December 19,2013

Meyer Pharmaceuticals, LLC, Irvine, California, United States

NCT02529579

Recruiting

iAPA-DC/CTL

Phase 1

Phase 2

June 2015–December 2019

Changhai Hospital, Second Military Medical University, Shanghai, China

NCT03638193

Recruiting

CAR-T-meso cells

Not Applicable

July 11, 2018-February 1, 2022

Nanjing First Hospital, Nanjing, Jiangsu, China

NCT03013712

Recruiting

CAR-T cells targeting EpCAM

Phase 1

Phase 2

January 2017–December 2020

IEC of Chengdu Medical College

Chendu, China

NCT01583686

Terminated

Anti-mesothelin CAR transduced PBL

Phase 1

Phase 2

May 4, 2012-December 17, 2018

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

NCT01420874

Active, not recruiting

EGFR2Bi-coated T cells

Phase 1

August 2011–June 2019

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

NCT03638206

Recruiting

Mesothelin targeting CAR-T cells

Phase 1

Phase 2

March 1, 2018-March 1, 2023

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

NCT00909558

Suspended

Autologous natural killer/natural killer T cell

Phase 1

May 2009, the last update posted is February 24, 2010

Envita Medical Centers, Scottsdale, Arizona, United States

NCT02839954

Unknown

Anti-MUC1 CAR-pNK cells

Phase 1

Phase 2

July 2016–July 2018

PersonGen BioTherapeutics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China

NCT00019084

Completed

Tumour-infiltrating lymphocytes

Phase 2

February 1996–May 2003

Medicine Branch, Bethesda, Maryland, United States

NCT03093688

Recruiting

iNKT cells and CD8+ T cells

Phase 1

Phase 2

March 1, 2017-December 31, 2019

Shanghai Public Health Clinical Center, Shanghai, Shanghai, China

NCT01174121

Recruiting

Young tumour-infiltrating lymphocytes

Phase 2

August 26, 2018-December 27, 2024

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

NCT01801852

Unknown

NKT cells

Not Applicable

January 2013–June 2017

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

NCT02465983

Completed

CAR-T-meso-19 T cells

Phase 1

May 2015–November 2017

University of California, San Francisco, San Francisco, California, United States

NCT02757391

Not yet recruiting

CD8+ T cells

Phase 1

December 31, 2018-December 31, 2022

M D Anderson Cancer Center, Houston, Texas, United States

NCT03269526

Active, not recruiting

Anti-CD3 x anti-EGFR bispecific antibody (EGFRBi) armed activated T cells (EGFR BATs)

Phase 1

Phase 2

July 28, 2017-June 1, 2022

University of Virginia, Charlottesville, Virginia, United States

NCT03682744

Recruiting

Anti-CEA CAR-T cells

Phase 1

September 13, 2018-September 2019

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Roger Williams Medical Center, Providence, Rhode Island, United States

NCT03407040

Enrolling by invitation

Generation of cancer antigen-specific T cells from human-induced pluripotent stem cells (iPSCs)

Phase:

January 30, 2018-December 31, 2030

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NCT03745326

Recruiting

Anti-KRAS G12D mTCR PBL

Phase 1

Phase 2

January 16, 2019-December 1, 2028

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NCT03190941

Recruiting

Anti-KRAS G12V mTCR

Phase 1

Phase 2

September 21, 2017-June 29, 2028

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NCT02850536

Active, not recruiting

Anti-CEA CAR-T cells

Phase 1

February 1, 2017-August 2018

University of Colorado Hospital, Aurora, Colorado, United States

Roger Williams Medical Center, Providence, Rhode Island, United States